A May 7, 2013 report from the ARISTOTLE trial was highlighted on The Heart.Organd showed superior efficacy for apixaban versus warfarin in stroke, systemic embolism, and all-cause death.
The Heart.org also provided this nicely illustrated and definitive European Heart Rhythm Association guide to the use of the new oral anticoagulants, including edoxaban, the most recent direct anti-Xa inhibitor under late-stage development byDaiichi Sankyo.
No comments here.